Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

38 results about "Poor adherence" patented technology

Forgetfulness is the most common patient factor leading to poor adherence, while personal or emotional issues can also affect adherence. 16. Providers may unintentionally influence adherence due to limited familiarity with drug costs and/or limited knowledge of insurance coverage and formularies.

Apparatus and method for prediction and management of participant compliance in clinical research

A system for developing and implementing empirically derived algorithms to generate decision rules to determine participant noncompliance and fraud with research protocols in clinical trials allows for the identification of complex patterns of variables that detect or predict participant noncompliance and fraud with research protocol, including performance and enrollment goals, in the clinical trial. The data may be used to overall predict the performance of any participant in a clinical trial, allowing selection of participants that tend to produce useful, high-quality results. The present invention can also be used to monitor participant compliance with the research protocol and goals to determine preferred actions to be performed. Optionally, the invention may provide a spectrum of noncompliance, from minor noncompliance needing only corrective feedback, to significant noncompliance requiring participant removal from the clinical trial or from future clinical trials. The algorithms and decision rules can also be domain-specific, such as detecting non-compliance or fraud among subjects in a cardiovascular drug trial, or demographically specific, such as taking into account gender, age or location, which provides for algorithms and decision rules to be optimized for the specific sample of participants being studied.
Owner:ERESTECH

Methods and systems for monitoring and enhancing patient compliance with a health treatment program

Methods and systems for enabling and supporting patient compliance with a health treatment program or with health-related instructions from a caregiver are described. An interactive feedback loop is implemented that enhances and improves on present methods of monitoring and supporting patient compliance with treatment programs, particularly for patients with chronic conditions. A patient enters various types of data (e.g., biometric readings, diary entries, responses to surveys and health assessments, etc.) to a health data management system that includes a patient compliance monitoring system. The patient is encouraged to enter as much data as is practical and as frequently as possible. The feedback loop of the present invention provides compliance messages to the patient in a timely manner that are responsive to the data entered by the patient. The messages are customized, supportive, and timely. The system can also implement a reward scheme in which patients who go beyond their prescribed treatment program or consistently stay within a compliance range obtain direct financial benefits or rewards. The system also allows patients to sends feedback on the messages he or she receives from the system. This feedback can be used to measure the effectiveness of a treatment program or of the monitoring system itself. Healthcare professionals play an active role in tailoring and “signing off” the compliance-related messages that the patient receives.
Owner:IMETRIKUS

Computer system and method for generating healthcare risk indices using medication compliance information

A healthcare risk index is generated using a patient or individual's pharmacy claims. The index may be used to explain and predict variation in pharmacy-related costs and variation in total healthcare costs or utilization. In particular, the index is generated by first examining the individual's pharmacy claims to identify any chronic conditions possessed by the individual. Similarly, the individual's pharmacy claims are examined to identify any compliance medications prescribed to the individual. The chronic condition information is used to generate a chronic condition score by summing regression coefficients for each chronic condition possessed by the individual. Likewise, the compliance medication information is used to generate a compliance medication score by summing products of regression coefficients for each compliance medication prescribed to the individual with associated medication supply weights. From there, a modified chronic condition score is generated by multiplying the chronic condition score by an overall chronic condition regression coefficient. The modified chronic condition score may then be further modified by subtracting a no-claims weight from the chronic condition score in cases where the individual has no pharmacy claims. Finally, the risk index may be determined by summing the modified chronic condition score and the compliance medication score.
Owner:EXPRESS SCRIPTS STRATEGIC DEV INC

Novel dosage form containing albendazole and application and preparation method thereof

The invention discloses a novel dosage form containing albendazole and application and a preparation method thereof. The novel dosage form mainly takes the mixture of albendazole and pamoic acid pyrantel as a medicinal composition, and an excipient and a flavoring agent are added to the medicinal composition to be made into granules. The novel dosage form contains 500-800 parts of medicinal composition, 40-120 parts of excipient and 50-100 parts of flavoring agent in parts by weight. The granules have the advantages of good drug disperse states, short disintegration time, rapid drug dissolution, rapid absorption, high bioavailability and the like and are convenient to take. The drug mouthfeel can be regulated according to the fondness of children, such as the apple taste, the lemon taste and the like. The novel dosage form is especially suitable for children, patients with special conditions and patients who are difficult to swallow. However, the children are parasitic disease susceptible populations but have poorer drug compliance. In order to increase the drug compliance of the children and improve the drug mouthfeel and the taking mode, designing the dosage form into the granules is extremely necessary. The invention also makes the orally taken dosage form of the compound albendazole granules diversified and simultaneously provides more selections for clinician and patient medications.
Owner:SICHUAN BAOSHENGKANG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products